Scholars@Duke

Response to Weidhaas and Slack re: Comments on "The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implication for clinical testing".

Publication ,  Journal Article
Risch, HA; Berchuck, A; Pharoah, PDP
Published in: Clin Cancer Res
October 15, 2011
Published version (DOI) Link to item

Duke Scholars

Andrew Berchuck
Author Andrew Berchuck Obstetrics and Gynecology, Gynecologic Oncology

Published In

Clin Cancer Res

DOI

10.1158/1078-0432.CCR-11-1504

EISSN

1557-3265

Publication Date

October 15, 2011

Volume

17

Issue

20

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Risch, H. A., Berchuck, A., & Pharoah, P. D. P. (2011). Response to Weidhaas and Slack re: Comments on "The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implication for clinical testing". Clin Cancer Res, 17(20). https://doi.org/10.1158/1078-0432.CCR-11-1504
Risch, Harvey A., Andrew Berchuck, and Paul D. P. Pharoah. “Response to Weidhaas and Slack re: Comments on "The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implication for clinical testing".” Clin Cancer Res 17, no. 20 (October 15, 2011). https://doi.org/10.1158/1078-0432.CCR-11-1504.
Risch, Harvey A., et al. “Response to Weidhaas and Slack re: Comments on "The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implication for clinical testing".” Clin Cancer Res, vol. 17, no. 20, Oct. 2011. Pubmed, doi:10.1158/1078-0432.CCR-11-1504.

Published In

Clin Cancer Res

DOI

10.1158/1078-0432.CCR-11-1504

EISSN

1557-3265

Publication Date

October 15, 2011

Volume

17

Issue

20

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis